MX2017014471A - Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy. - Google Patents

Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy.

Info

Publication number
MX2017014471A
MX2017014471A MX2017014471A MX2017014471A MX2017014471A MX 2017014471 A MX2017014471 A MX 2017014471A MX 2017014471 A MX2017014471 A MX 2017014471A MX 2017014471 A MX2017014471 A MX 2017014471A MX 2017014471 A MX2017014471 A MX 2017014471A
Authority
MX
Mexico
Prior art keywords
clonidine
radiotherapy
prevention
skin injury
derivatives
Prior art date
Application number
MX2017014471A
Other languages
Spanish (es)
Inventor
Vasseur-Demarcy Bérangère
Attali Pierre
Original Assignee
Monopar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monopar Therapeutics Inc filed Critical Monopar Therapeutics Inc
Publication of MX2017014471A publication Critical patent/MX2017014471A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C07C25/08—Dichloro-benzenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.
MX2017014471A 2015-05-13 2016-05-10 Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy. MX2017014471A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305728 2015-05-13
PCT/EP2016/060466 WO2016180834A1 (en) 2015-05-13 2016-05-10 Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy

Publications (1)

Publication Number Publication Date
MX2017014471A true MX2017014471A (en) 2018-06-11

Family

ID=53199907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014471A MX2017014471A (en) 2015-05-13 2016-05-10 Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy.

Country Status (13)

Country Link
US (1) US11090290B2 (en)
EP (1) EP3294292A1 (en)
JP (1) JP7102147B2 (en)
KR (1) KR20180004784A (en)
CN (1) CN107708691A (en)
AU (1) AU2016260785B2 (en)
BR (1) BR112017024356A2 (en)
CA (1) CA2985689A1 (en)
HK (1) HK1251178A1 (en)
IL (1) IL255544B (en)
MX (1) MX2017014471A (en)
WO (1) WO2016180834A1 (en)
ZA (1) ZA201707603B (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
FR2665357B1 (en) 1990-07-31 1995-03-31 Aiache Jean Marc PROCESS FOR THE PREPARATION OF A BIO-ADHESIVE GALENIC FORM AND GALENIC FORM THUS PREPARED.
AU2002235175A1 (en) * 2000-12-06 2002-06-18 Tularik, Inc. Lometrexol combination therapy
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
FR2889417B1 (en) 2005-08-05 2008-02-08 Roquette Freres TEXTUREED PEAS PROTEINS
EP1972332A1 (en) 2007-03-23 2008-09-24 BioAlliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
EP2368549A1 (en) 2010-03-25 2011-09-28 BioAlliance Pharma Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
AU2012281059A1 (en) 2011-07-14 2014-02-06 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
US20150272934A1 (en) 2012-07-25 2015-10-01 Sova Pharmaceuticals, Inc. Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders

Also Published As

Publication number Publication date
AU2016260785B2 (en) 2022-06-02
IL255544A (en) 2018-01-31
JP2018519271A (en) 2018-07-19
CA2985689A1 (en) 2016-11-17
EP3294292A1 (en) 2018-03-21
HK1251178A1 (en) 2019-01-25
KR20180004784A (en) 2018-01-12
BR112017024356A2 (en) 2018-07-31
IL255544B (en) 2020-09-30
US20180098967A1 (en) 2018-04-12
AU2016260785A1 (en) 2017-11-30
ZA201707603B (en) 2019-05-29
JP7102147B2 (en) 2022-07-19
WO2016180834A1 (en) 2016-11-17
CN107708691A (en) 2018-02-16
US11090290B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MX2021013139A (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient.
PH12016502352A1 (en) Pharmaceutical composition
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
MX2016016400A (en) Stabilized oxymetazoline formulations and their uses.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2019012522A (en) Therapeutic compounds and methods.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2017014471A (en) Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy.
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
PH12016502527B1 (en) Stabilized desmopressin
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
TR201719926A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE LITHIUM SALTS AND VITAMIN C
TH167850B (en) (R) - Perlindole And its pharmacologically acceptable salt for use in medicinal drugs.
EA201691599A1 (en) COMBINATION OF TAURINE AND RACEMETIONINE FOR THE TREATMENT OF LIVER DISEASES
IN2014DE00822A (en)